Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00307398 · ClinicalTrials.gov registry record · Phase 3
Anecortave Acetate Risk-Reduction Trial (AART)
A Phase 3 study, sponsored by Alcon Research.
- Terminated
- Registry status
- Phase 3
- Development phase
- 2,596
- Enrollment target
NCT00307398: Clinical Trial Phase 3 study, sponsored by Alcon Research.
NCT00307398 is a Phase 3 study that was terminated before completion, run by Alcon Research. The registered enrollment target is 2,596 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (236% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00307398, a Phase 3 study, was terminated before completion, sponsored by Alcon Research.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2,596 participants
- Enrollment target
Study Summary
A 48 month study of posterior juxtascleral administrations of Anecortave Acetate 15 or 30 mg or sham administration every 6 months.
Primary Outcome
ST-CNV is defined as CNV or a portion of CNV within 2500 microns of the foveal center, as evidenced by digital angiography at the clinical site.
Interventions
- OTHER Anecortave Acetate Vehicle
- DRUG Anecortave Acetate (AL-3789) sterile suspension, 15 mg or 30 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,596 participants |
| Start Date | 2004-03 |
| Est. Completion | 2009-01 |
| Phase | Phase 3 |
Why NCT00307398 stopped before completion
NCT00307398 is an interventional study that assigns participants to a tested intervention. Its 2,596 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (236% higher).
The record links to 0 conditions, and to 2 interventions - of which Anecortave Acetate Vehicle is the first listed.
NCT00307398 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00307398 about?
NCT00307398 is a clinical study titled "Anecortave Acetate Risk-Reduction Trial (AART)". A 48 month study of posterior juxtascleral administrations of Anecortave Acetate 15 or 30 mg or sham administration every 6 months.
What is the current status of trial NCT00307398?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2,596 participants. The study started on 2004-03. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00307398?
The interventions under investigation include: Anecortave Acetate Vehicle (OTHER), Anecortave Acetate (AL-3789) sterile suspension, 15 mg or 30 mg (DRUG).
Who is sponsoring clinical trial NCT00307398?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00307398's enrollment target sits among peer trials
2,596 85th of 2000 higher than 1,916 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06033950 · 2,600 participants · Phase 3
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
- NCT06574672 · 2,600 participants · NA
Embedded Palliative Care in the MICU
- NCT06370520 · 2,592 participants
Screening Emotions in Adolescents at the Hospital for mTBI
- NCT06018285 · 2,572 participants · NA
Stepped Approach to Reducing Risk of Suicide in Primary Care
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia